Cellular Intelligence Buys Rights to Novo's Phase 1/2 Parkinson's Therapy for 12 Million Patients
Updated
Updated · The Jerusalem Post · May 11
Cellular Intelligence Buys Rights to Novo's Phase 1/2 Parkinson's Therapy for 12 Million Patients
15 articles · Updated · The Jerusalem Post · May 11
Cellular Intelligence took global control of Novo Nordisk’s clinical-stage Parkinson’s cell therapy, an allogeneic stem-cell-derived dopaminergic progenitor treatment already in a first-in-human Phase 1/2 trial.
FDA Fast Track status and IND clearance give the startup a ready clinical base as it applies its AI model—trained on millions of cellular perturbations—to speed development, manufacturing and commercialization.
Novo Nordisk will buy an equity stake and remain eligible for milestone payments and royalties, though financial terms were not disclosed.
The handoff follows Novo’s broader retreat from several cell-therapy programs during a cost-cutting restructuring, while Cellular Intelligence named former AbbVie, Bial and Novartis executive Nuno Mendonça as chief medical officer.
Can an AI startup truly outpace biology's limits to fast-track a Parkinson's drug for a pharma giant?
When an AI designs a drug trial, who is liable if its 'black box' predictions cause patient harm?
Novo Nordisk Hands Off Parkinson’s Cell Therapy to AI Startup Cellular Intelligence in $62M-Backed Deal, Marking Major Strategic Shift
Overview
Novo Nordisk has formed a strategic partnership with Cellular Intelligence to accelerate the development of an experimental Parkinson’s disease therapy. By transferring the rights to its early-stage treatment, Novo Nordisk allows Cellular Intelligence to take the lead in guiding the therapy through clinical trials. This collaboration leverages Cellular Intelligence’s advanced AI capabilities to speed up the process, while Novo Nordisk stands to receive milestone payments and royalties if the program succeeds. The partnership reflects Novo Nordisk’s shift in focus and highlights how AI-driven biotech startups can play a key role in advancing complex therapies more efficiently.